GSK_ Annual_Report_2021-22

Notes to the Consolidated Financial Statements for the year ended March 31, 2022 253 (iii) Disclosure in respect of material transactions with parties referred to in item 1(i) and 1(ii) above: ( ` in lakhs ) Year ended March 31, 2022 Year ended March 31, 2021 (a) Purchase of materials/traded goods: GlaxoSmithKline Asia Private Limited, India - 12,33.36 GlaxoSmithKline Biologicals S.A., Belgium 329,92.43 540,30.11 GlaxoSmithkline Pharma India Pvt. Ltd. 15,53.70 10,51.03 GlaxoSmithKline Export Limited, U.K. 87,16.13 66,58.74 (b) Sale of materials/sale of products: GlaxoSmithKline Trading Services Limited, Ireland - 63.17 GlaxoSmithKline Asia Private Limited, India (Refer Note 55) 65.19 - GlaxoSmithKline Export Limited, U.K. 74,00.45 9,32.79 (c) Purchase of Vaccines business: GlaxoSmithKline Asia Private Limited, India 1,66.00 - (d) Purchase of license: GSK Consumer Healthcare Pte Ltd., Singapore 8,99.82 - (e) Sale of brands and other identified assets: GlaxoSmithKline Asia Private Limited, India 1639,84.36 - (f) Expenses recharged to other companies: GlaxoSmithKline Asia Private Limited, India 5.77 5,74.13 GSK India Global Services Private Limited 6,57.22 2,89.03 GSK Pharmaceuticals Pvt. Ltd. , Srilanka 64.78 36.73 GlaxoSmithKline Pharmaceuticals S.A., Belgium - 5.65 GlaxoSmithKline Export Limited, U.K. 1,56.07 4,15.60 GlaxoSmithKline Biologicals S.A., Belgium - 1,60.00 GlaxoSmithKline Research & Development Ltd, U.K. 1,01.65 10.34 GlaxoSmithKline Services Unlimited, U.K. 2,08.42 4,59.07 Glaxo Operations UK Limited, U.K. 1,05.51 4,59.91 GlaxoSmithKline Trading Services Limited, Ireland 11.86 2,97.64 (g) Expenses recharged by other companies: GlaxoSmithKline Services Unlimited, U.K. 1,32.55 1,19.84 SmithKline Beecham Pharmaceuticals, U.S.A. - 97.50 SmithKline Beecham Limited, U.K. - 30.22 GlaxoSmithKline Pte Limited, Singapore 7.50 49.56 GlaxoSmithKline Asia Private Limited, India 142,05.55 93,87.51 (h) Manufacturing charges recovered: GlaxoSmithKline Asia Private Limited, India - 4,31.95 (i) Clinical research and data management recoveries: GlaxoSmithKline Biologicals S.A., Belgium 5,27.01 7,84.03 GlaxoSmithKline Research & Development Ltd, U.K. 93.35 1,00.44 (j) Interest income on loan given: GSK India Global Services Private Limited 3,19.58 - (k) Loans given: GSK India Global Services Private Limited 190,00.00 - (l) Liabilities written back: GlaxoSmithKline South Africa (Pty) Ltd., South Africa - 77.24 (m) Employee benefit liabilities transferred to a related party: GlaxoSmithKline Asia Private Limited, India - 19.86